Chee Kong Choo has bought GDTC on 2 days since May 2026

Choo Chee Kong is a Singapore-based corporate finance executive and entrepreneur who serves as Chairman and Director of CytoMed Therapeutics Ltd. (NASDAQ: GDTC), where he is also a major shareholder and corporate insider.( He has chaired CytoMed since its incorporation in March 2018 and beneficially owns a significant stake in the company through both direct holdings and interests in entities such as Glorious Finance Limited and EP Capital Inc.( Mr. Choo has more than 20 years of experience in corporate finance, overseeing strategic direction, expansion plans, and corporate governance in multiple listed companies.(

Beyond CytoMed, Choo Chee Kong is Executive Vice Chairman of CNMC Goldmine Holdings Limited, listed on the Singapore Exchange, where he is responsible for formulating strategic direction and growth initiatives.( Earlier in his career, he spent about 14 years at DBS Bank Ltd. in Singapore (1986–2000) and later founded Westcomb Financial Group Limited, a corporate advisory and stockbroking boutique that he listed on SGX in 2004 and led as CEO until 2008.( He has also held independent and non‑executive directorships at several SGX-listed companies, including Second Chance Properties Ltd., FDS Networks Group Ltd., and Advance SCT Limited.( Mr. Choo holds a Bachelor of Engineering in Mechanical Engineering (First Class Honours) from the University of Liverpool (1981) and an MBA from the University of Bradford (1985).(

Written by Perplexity from public sources.